Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVAS-an interesting california-based biotech company here -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (106)	12/3/2002 7:18:26 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 126

ASH Preview Dr. Leon Henderson will be attending the American Society of Hematology meeting in Philadelphia beginning this Friday. We expect the most valuable presentations to be related to Millennium’s (NASDAQ: MLNM) Velcade and AstraZeneca’s (NYSE: AZN) Exanta. Presentations should also benefit Celgene (NASDAQ: CELG), IDEC (NASDAQ: IDPH), Genentech (NYSE: DNA), Novartis (NYSE: NVS), Sanofi Synthélabo (NYSE: SNY), and Corvas (NASDAQ: CVAS). Although we are seeing less frequent release of new data that immediately impact developmental drugs, major medical meetings are forums for medical expert interaction and appraisal that influence drug usage. We also often see confirmation or rejection of less formally presented material. Millennium’s Velcade will be the topic of considerable discussion as a more complete phase II data set is revealed, supporting ongoing phase III efforts in multiple myeloma management. Velcade is a novel cancer therapeutic that functions by inhibiting the proteasome, an intracellular garbage processing plant. Several anticoagulant drugs will be discussed at the meeting. AstraZeneca’s Exanta, a direct thrombin inhibitor, is beginning to demonstrate its future place as an oral anti-blood clotting alternative to Sanofi and Organon’s Arixtra, a parenteral direct thrombin inhibitor. Arixtra needs to continue to distinguish itself from both marketed anticoagulants as well as Exanta and Corvas’s rNAPc2. rNAPc2, an injectable anticoagulant derived from nematodes might find the path of least resistance to market the management of coronary arterial clots as opposed to the venous clot focus of Arixtra and Exanta. Evidence of rNAPc2’s efficacy in patients undergoing elective percutaneous coronary interventions will generate extensive dialogue. biospace.com (I could not find where cvas is on stage. There is one lonely CVAS abstract on small human endotoxin challenge.)